作者: Louise van der Weyden , David J. Adams
DOI: 10.1016/J.BBCAN.2007.06.003
关键词:
摘要: Ras proteins play a direct causal role in human cancer with activating mutations occurring ∼ 30% of tumours. effectors also contribute to cancer, as occur effectors, notably B-Raf and PI3-K, drugs blocking elements these pathways are clinical development. In 2000, new effector was identified, RAS-association domain family 1 (RASSF1), expression the RASSF1A isoform this gene is silenced tumours by methylation its promoter. Since reversible demethylating agents currently being used trials, detection silencing promoter hypermethylation has potential uses diagnosis, prognosis treatment. belongs RAS which there 8 members (RASSF1–8). RASSF1–6 each contain variable N-terminal segment followed Ras-association (RA) Ral-GDS/AF6 type, specialised coiled-coil structure known SARAH extending C-terminus. RASSF7–8 an RA Members RASSF thought function tumour suppressors regulating cell cycle apoptosis. This review will summarise our current knowledge member particular what they tumourigenesis, special focus on RASSF1A, whose one most frequent alterations found